Antiretroviral treatment failure and associated factors among HIV patients on the first-line antiretroviral therapy at Mian-Tepi University teaching hospital, Southwest Ethiopia

A cross-sectional study

Jafer Siraj, BPharm, MSc, Desalegn Feyissa, BPharm, MSc, Yitagesu Mamo, BPharm, MSc, Ameha Zewudie, BPharm, MSc, Tolcha Regesa, BPharm, MSc, Fikadu Ejeta, BPharm, MSc, Diriba Feyisa, BPharm, MSc, Gemmechu Hasen, BPharm, MSc, Tesfaye Mohammed, BPharm, MSc, Temesgen Aferu, BPharm, MSc

Abstract

The use of Antiretroviral therapy (ART) has become a standard of care for the treatment of HIV infection. The therapy restores immune function and reduces HIV-related adverse outcomes. However, treatment failure erodes this advantage and leads to an increased morbidity and compromised quality of life in HIV patients. Thus, this study aimed to assess anti-retroviral treatment failure and associated factors among HIV patients on the first-line ART at Mian-Tepi University Teaching Hospital. A cross-sectional study was undertaken among adult patient who have been on ART and attending ART Clinic of Mian-Tepi University Teaching Hospital from September 2014 to September 2018. Data were collected retrospectively by reviewing patients’ medical charts using a standard structured questionnaire. Data were entered into Epi data version 4.0.2 and then exported to SPSS version 21.0 for analysis. To identify the predictors of anti-retroviral treatment failure, multiple stepwise backward logistic regression analysis were done. P value < 0.05 was considered as statistically significant. Among 221 patients included in the study, 118 (53.39%) were females. The mean weight of study participants at ART initiation was 57.04 kg. Of the 221 patients on the first line ART, 10 (4.5%) experienced treatment failure. Of these patients, 5 (50%) and 2 (30%) experienced virological failure and clinical failure, respectively. Functional status (AOR: 3.7, CI: [1.13–6.5]), P < .001) and low baseline CD4 cell count (AOR: 4.3, CI: [3.4–10.6]), P < .001) were found to be independent predictors of treatment failure. The rate of first-line ART treatment failure in the study setting was substantial. Functional status and low baseline CD4 cell count were found to be independent predictors of virological, clinical and immunological failure. Therefore, more attention should be given for the lifestyle of patients’ on ART and maximize virological tests for monitoring treatment failures.

Abbreviations: AIDS = Acquired Immune Deficiency Syndrome, ART = Anti Retroviral Therapy, cART = Combination Anti-Retroviral Therapy, CD4 = Clusters of Differentiation, HAART = Highly Active Anti-retroviral Therapy, HIV = Human Immunodeficiency Virus, HIVDR = HIV Drug Resistance, MDR-TB = Multi-Drug Resistance Tuberculosis, MTUTH = Mian Tepi University Teaching Hospital, NRTI = Nucleoside Reverse-Transcriptase Inhibitors, PCP = Pneumocystis Carnivi Pneumonia, PTB = Pulmonary Tuberculosis, PUD = Peptic Ulcer Disease, UTI = Urinary Tract Infection, WHO = World Health Organization.

Keywords: antiretroviral, Ethiopia, Mizan Tepi University teaching hospital, treatment failure
1. Introduction

The identification and management of first-line ART failure is a key challenge for HIV programs in resource-limited settings. Staying on a failing first-line therapy is associated with an increased mortality. In addition to this, development of drug resistance limits the ability to construct new, potent, and tolerable regimens in the future. This study was aimed to determine the first-line ART failure and factors associated with it. Highly active antiretroviral treatment (HAART) has been effective in prolonging and improving the quality of life of people living with HIV by transforming it from a fatal acute disease to a manageable chronic condition.[1]

Human immunodeficiency virus (HIV) is responsible for a worldwide pandemic, and is the cause of acquired immune deficiency syndrome (AIDS). The 2020 Joint United Nations programme on HIV/AIDS (UNAIDS) report indicated about 3.5 million more HIV infections and 820,000 people died from AIDS-related illnesses in the same year.[2,3] Over the past three decades, there has been an unparalleled effort to provide access to antiretroviral therapy (ART) for HIV-infected individuals in sub-Saharan Africa, the region with the highest HIV burden.[4] Global scale-up of antiretroviral therapy has been the primary contributor to a 48% decline in deaths from AIDS-related causes.[5]

Viral load monitoring has become the standard of care for monitoring the success of and diagnosing the failure of ART and has been explicitly recommended by the World Health Organization (WHO) since 2010. In settings in which there is no access to viral load testing, clinical monitoring alone or a combination of clinical and immunologic monitoring is used to assess response to ART and to determine treatment failure.[6–8]

Studies conducted in different parts of Ethiopia showed the presence of treatment failure. The immunological failure rate in Debre Markos Hospital was found to be high.[9] Conversely, a study conducted in Gondar University Hospital showed that virologic failure rate was low (4.1%).[10] HIV treatment failure in Ethiopia found to be high. Being on advanced WHO clinical stage, presence of opportunistic infections, and poor adherences to highly active antiretroviral therapy were the contributing factors of HIV treatment failure.[11] In another study, treatment failure among ART users in Ethiopia was significant. Adherence, co-infection, advanced WHO clinical stage, regimen change, and disclosure are determinant factors for treatment failure.[12]

Studies revealed that baseline clinical factors (e.g., high pretreatment viral load, low pretreatment CD4 count, prior WHO stage), drug-drug interactions, poor adherence, primary infection with drug-resistant strains of HIV were associated with treatment failure.[13,14] In addition, inappropriate prescribing, poor patient retention on ART or late initiation or when stock-outs occur have been shown to be associated with the development of HIV treatment failure.[15–18] Lower prevalence of HIV treatment failure based on the definition of HAART, immunological, and virological failure was 13.7% in Amhara, 6.5% in Tigray, and 1.5% in Addis Ababa, respectively.[11] Failure can be assessed, based on WHO criteria, as clinical, immunologic, virologic or a combination. Regular treatment failure detection is low because of inadequate capacity and lack of laboratory facilities in resource-limited settings including Ethiopia.[19]

The timing and accuracy of treatment failure in resource-limited settings is fundamental. Early detection of treatment failure is crucial to sustain first-line therapy effectiveness. Inability to do so may lead to the accumulation of drug resistance-associated mutations and may result in increased morbidity and mortality. However, misclassification due to the need for early detection of treatment failure lead to the premature switch and use of valuable second-line regimens, which are costly and may represent the last available regimen.[20–23]

Identification of risk factors helps to early define predictors of treatment efficacy that permit better use of these potent drugs, avoid unnecessary side effects of second-line drugs, prevent drug resistance, and reduce economic burden, especially in a resource-limited setting like Ethiopia. It also helps as a guide for health professionals and higher officials to alleviate the problem and to develop strategies to decrease the rate of treatment failure. Despite such importance, information regarding anti-retroviral treatment failure and associated factors is null in the present study setting and therefore, this study aimed to assess anti-retroviral treatment failure and associated factors among HIV patients on first line ART at Mizan-Tepi University Teaching Hospital.

2. Methods

2.1. Study setting and period

The study was conducted in Mizan-Tepi University Teaching Hospital (MTUTH), Bench Sheko Zone, Southern Nations, Nationalities and Peoples Region (SNNPR), Ethiopia. The Hospital is located 585 km away from Addis Ababa, the capital city of Ethiopia and 830 km away from Hawasa, the capital city of SNNPR. The hospital has inpatient and outpatient departments and 4 different wards including medical ward, gynecology and obstetrics ward, pediatrics ward and surgical ward. It delivers diversified health services including emergency services, dental clinic, psychiatry clinic, laboratory services, X-ray, and follow up of chronic diseases like TB, and HIV/AIDS. The Hospital has Outpatient, Inpatient, Emergency and ART Pharmacies. The study was conducted from March 19 to April 5, 2019 through patient’s chart review to assess first line ART treatment failure and factors associated with ARV treatment failure.

2.2. Study design

A hospital based cross-sectional study was conducted among HIV patients on first line ART from September 2014 to September 2018 at MTUTH.

2.3. Source and study population

All adult patients living with HIV/AIDS who have enrolled for treatment at ART clinic of MTUTH were source population whereas, adult HIV patients who had received ART for at least 6 months within September 2014 to September 2018 time period and fulfilled the inclusion criteria were the study population. Adult HIV patients aged ≥18years, patients who had started standard first-line ART and had taken ART for at least 6 months were included in the study whereas, patients who were on second-line ART and had incomplete data were excluded from the study.

2.4. Patient and public involvement

Since the data were collected from patients’ medical chart, the patients were not directly involved in data collection process.
2.5. Outcomes variables

The dependent variable was ART treatment failure whereas, the independent variables consisted: baseline CD4 cell count, sex, age, WHO disease stage during ART initiation, marital status, educational status, religion, types of ART regimen, co-morbidity, presence of opportunistic infection, and duration of initial therapy.

Treatment failure can be defined as a progression of disease after initiation of Highly active Anti-retroviral Therapy (HAART). ART failure is associated with virologic failure, immunologic failure, and/or clinical failure. Immunological failure is defined as a fall in CD4 cell count to baseline (or below) or a 50% reduction from on treatment peak value or presence of persistent CD4 cell count below 100 cells/mm$^3$. Clinical failure is the occurrence of new or recurrent WHO stage 4 or some stage 3 conditions. Virological failure is said to have occurred when plasma viral load exceeds 1000 copies/mL in two consecutive measurements within a 3-month interval with adherence support after at least 6 months of following ART.

2.6. Sample size determination and sampling technique

The sample size was determined based on the single population proportion formula: \( (Z\alpha/2)^2 \times p(1-p)/d^2 \) with the assumption of 95% confidence interval (CI), marginal error \( d \) of 5%, \( Z\alpha/2 = 1.96 \), and \( P = 50\% \). Accordingly, the sample size was found to be 384. Then, using the correction formula \( N_f = n/(1 + n/N) \) with \( N = 521 \) (the number of patients on ART from September 2014 to September 2018), the required total sample size was calculated to be 221. Simple random sampling was utilized to include adult patients who fulfilled the inclusion criteria and whose charts were complete during the data collection period.

2.7. Data collection tool

The data was collected by reviewing patient charts of HIV patients who fulfilled the inclusion criteria. A data abstraction format which contained patient’s socio-demographic data, baseline characteristics and treatment related data was prepared. After the abstraction format was prepared patient charts was reviewed and baseline demographic data at the time of ART initiation were recorded including sex, age at ART initiation, weight at ART initiation, marital status, religion, educational status, and substance abuse. Baseline data including significant co-morbid illness, laboratory data such as functional status at ART initiation, AIDS defining illness prior to ART were collected. Treatment related data such as, WHO stage at ART initiation, CD4 count initially, history of treatment interruption, initial first line regimen and ART failure related data such as type of treatment failure, reason for treatment failure, failing ART regimen were studied.

2.8. Data collection and procedures

Data was collected from patients medical chart through reviewing. That means, collecting important and detailed information present in the medical chart and used for study. The medical chart review (data collection process) took place at Mizan-Tepi university teaching hospital. To avoid errors and omissions, the data collectors were trained professionals who have been working at this area for more than 2 years and also training was given before data collection. The supervisors were assigned and followed the data collectors daily. Daily thorough reviews of the collected data were put in place and important corrections were given on the subsequent days. Double entry was made to prevent error.

2.9. Quality assurance and control

Data abstraction format were prepared based on literature. To assure the quality of collected data appropriately, designed data collection instrument was used and the collected data were reviewed and checked for completeness and consistency. The Cronbach’s alpha coefficient of the data collection tool was calculated to check internal consistency and it was 0.79 which is within the acceptable range.

Unavailable data on patient charts and which were not related to the study objectives were omitted (specially WHO disease stage, CD4 count level, initial first line ART regimen, functional status). Flow diagram of numbers of potentially eligible, examined for eligibility, confirmed eligible, included in the study, and analyzed was expressed in Figure 1.

2.10. Data processing and analysis

The data were explored to check for outliers, missing data and assumptions. During analysis, frequencies and percentages were used to describe categorical variables, while means and standard deviations were used to describe continuous variables. Bivariate logistic regression was run for all independent variables to identify variables that fits for multivariable logistic regression. Variables with a \( P \)-value \(< .25 \) in the bivariate analysis were included in multivariable logistic regression model to identify the predictors of ART treatment failure. A \( P \)-value \(< .05 \) was considered significant.

2.11. Ethical clearance

The ethical clearance was obtained from Mizan-Tepi University research ethical board. The hospital director was informed about the purpose of the study to get agreement. Patients had requested for informed consent. To ensure patient confidentiality, name and address of the patient was not recorded in the data collection format.

2.12. Operational definition

- cART is defined as a treatment regimen containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) (either nevirapine or efavirenz), or a protease inhibitor (PI) plus 2 nucleoside reverse transcriptase inhibitors (NRTIs), or triple NRTIs (zidovudine/lamivudine/ abacavir).
- Treatment failure is defined as progression of disease after initiation of HAART.
- Virological failure is defined as an inability to reach a viral load >1000 copies/mL after a defined amount of time.
- Immunologic failure is when CD4 count falls to the base line (below or 50%) from on treatment peak value or persistent CD4 level below 100 cell/mm$^3$ without concomitant infection to cause transient CD4 cell decreaseament.
- Clinical failure is defined as New or recurrent WHO stage 4 conditions occurred and certain WHO stage 3 conditions.
3. Results

3.1. Socio-demographic characteristics of study participants

Out of 221 patients included in the study, 118 (53.39%) patients were females. The mean age of patients at the start of ART was 31.16 ± 0.34 years (range 18–70 years). Nearly half of the patients were the Orthodox Christians (52.5%) and had attended primary education (48.9%). Nearly one fourth of them had a history of substance abuse (27.3%) (Table 1).

3.2. Baseline clinical characteristics of patients

The mean CD4 count at ART initiation was 255.35 cells/mm³ (range 19–848 cell/mm³). Majority of study participants, 86 (38.6) and 65 (29.4) were at WHO stage I and stage III condition at time of ART initiation, respectively. Fifty-two (23.5%) of patients had one or more opportunistic infection at the time of their HAART initiation. Most of the patients 190 (86%) were working by their functional status and 34 (15.4%) had significant co-morbid illness at the start of HAART, of which the majority of them 18 (52.9%) suffered pulmonary tuberculosis (PTB) (Table 2).

3.3. Treatment-related information

The majority of the patients were on tenofovir-lamivudine-efavirenz 174 (78.7%). All most 207 (93.7%) had good adherence to their treatment. Majority of patients 80.01% were followed their treatment for >12 months and, all most 205 (92.8%) have no history of treatment interruption (Table 3).

3.4. Treatment failure

A total of 10 (4.5%) patients were found to have treatment failure. The main documented reason for treatment failure was non-adherence 8 (80%) of patients. As shown in Table 4, majority of treatment failure cases were on a regimen with zidovudine +lamivudine backbone which is 70%. In most of the cases, the patients had both virological and clinical failure (Table 4).

3.5. Factors associated with treatment failure

Bedridden functional status, history of treatment failure, and low baseline CD4 count (<100 cells/mm³) were the factors associated with treatment failure in binary logistic regression analysis.

Figure 1. Schematic presentation of the sampling procedure of the study subjects.

Table 1
Socio-demographic characteristics of HIV/AIDS patients on antiretroviral therapy at MTUTH from September 2014 to September 2018.

| Variable          | Category       | Frequency (%) |
|-------------------|----------------|---------------|
| Sex               | Female         | 118 (53.4)    |
|                   | Male           | 103 (46.6)    |
| Age               | 18–30          | 120 (54.29)   |
|                   | 31–45          | 89 (40.27)    |
|                   | 46–60          | 11 (4.9)      |
|                   | >60            | 1 (0.45)      |
| Weight at ART initiation | 35–50       | 59 (26.69)    |
|                   | 51–65          | 123 (55.65)   |
|                   | >65            | 39 (17.64)    |
| Marital status    | Never married  | 48 (21.7)     |
|                   | Married        | 119 (53.8)    |
|                   | Divorced       | 38 (17.7)     |
|                   | Widowed        | 16 (7.2)      |
| Religion          | Orthodox       | 116 (52.5)    |
|                   | Muslim         | 67 (30.3)     |
|                   | Protestant     | 36 (16.3)     |
|                   | Protestant     | 2 (0.9)       |
| Educational status| Primary education | 108 (48.9)   |
|                   | No education   | 50 (22.6)     |
|                   | Secondary education | 42 (19)    |
|                   | Higher education | 21 (9.5)     |
| Substance Abuse   | No             | 174 (78.7)    |
|                   | Yes            | 47 (27.3)     |

* Catholic.
patients who had a baseline CD4 cell count $<200$ cells/mm$^3$ were more likely to develop treatment failure AOR $=4.3$ (1.04–10.6) (Table 5). Therefore, being bedridden and low CD4 count ($<200$ cell/mm$^3$) are independent predictors of treatment failure among patients on first-line ART in the study setting.

4. Discussion

This study showed that the prevalence of first-line ART failure rate was 4.5%. This finding was comparable with study conducted in Gondar which was 4.1%. However, this result was far from what was found in the study at Debremarkos Hospital, Ethiopia in which the failure rate was reported as 21%.

The possible explanation for the observed variations could be attributed to methodological difference in the assessment of failure, sample size, socio-economic, and medical service that has a great impact on treatment failure detection. This discrepancy might be also due to the difference in study setting and difference in experienced health care professionals involved in medication adherence and counseling.

In Ethiopia, the threat of HIV treatment failure is becoming a continuing discussion. This might be due to poor HIV care services, delayed to recognize treatment failure, late initiation of HAART, high burden of opportunistic infections, lack of appropriate nutritional support, ART-associated adverse reactions, and frequent psychological problem. Besides, the absence of frequent therapeutic drug monitors and/or resistance testing while the patient is still on the suspect or failing regimen. All four markers of lower socioeconomic status (financial hardship, non-employment, rented or unstable housing status, and non-university education) can be considered for the higher burden of HIV treatment failure in Ethiopia.

Even though the binary logistic regression showed many variables to have significant association with ART failure, multivariate logistic regression indicates that only poor adherence $80\%$ of the patients. In addition, majority of treatment failure cases were on a regimen with zidovudine +lamivudine backbone which is 70%. This is in line with the study done in Felege-Hiwot Referral hospital, Ethiopia where zidovudine +lamivudine backbone was the major regimen with treatment failure.

This study found that the patients with an initial CD4 cell count of $<100$ cells/mm$^3$ have more risk of developing treatment
failure than the patients with a higher baseline CD4 count. This might be due to the reason that the patients with a low baseline CD4 cell count have a lesser immunity that may favor the probability of developing immunological failure. Similarly, the study done in Thailand,[27] Debremarkos Ethiopia,[9] and Felege-Hiwot Referral hospital[3] reported that low baseline CD4 cell count is significant predictor of immunological failure. This might be due to the reason that the patients with a low baseline CD4 cell count have a lesser immunity that may favor the probability of developing immunological failure.

This study found that the patients with an initial ambulatory functional status have 23.50 times more risk of developing treatment failure than the patients with who had working functional status. This is inline with study done in Felege-Hiwot Referral hospital, Ethiopia[3] where patients with initial ambulatory functional status had high risk of developing treatment failure as compared to patients with working functional status. But, this finding contrasts with the studies conducted in St. Luke and Tulu Bolo hospitals and Tanzania, which indicated baseline functional status did not have an association with the hazard of treatment failure.[28,29] This inconsistency could be due to differences in criteria used to measure ART failure and follow-up period across studies. Bedridden functional status ART initiation reflects the deprived health condition and immunologic deterioration of patients. Therefore, patients are at increased risk of opportunistic infection, increased the burden of drugs and toxicity that could negatively affect adherence to ART medications and possibly increases the risk of ATR failure.

4.1. Limitations of this study

This is a retrospective chart review which may be prone to errors and omissions and a single-centered study, the result may not also be generalized to all hospitals. Thus, we suggest further prospective and multi-centered studies to be done. The study misses some important variables like drug side effects during follow-up, body mass index, status disclosure, and substance abuse at start of first-line ART which were not recorded for most of the patients.

5. Conclusion

In the present study setting, the prevalence of first-line ART failure was substantial. Treatment failure was most likely to occur for the patients who had working functional status and those who were delayed to start ART till their CD4 cell count became very low (<100 cells/mm³). functional status and low baseline CD4 cell count were an independent predictor of treatment failure among patients on the first-line ART. Early assessment of patient’s functional status and CD4 level may prevent treatment failure. Therefore, avoiding delays in ART initiation, reinforcing adherence interventions, and early CD4 cell count monitoring is important to prevent treatment failure.

Acknowledgments

We would like to extend our gratitude to Mizan-Tepi University for allowing us to conduct this study. We are also extended our gratitude to all individuals who involved in data collection.

Author contributions

All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Conceptualization: Jafer Siraj, Desalegn Feyissa.

Data curation: Jafer Siraj, Tolcha Regesa, Fikadu Ejeta, Gemmechu Hasen, Temesgen Aferu.

Formal analysis: Desalegn Feyissa, Yitagesu Mamo, Tolcha Regesa, Diriba Feyisa, Gemmechu Hasen, Temesgen Aferu.

Funding acquisition: Yitagesu Mamo, Fikadu Ejeta, Temesgen Aferu.

Investigation: Jafer Siraj, Diriba Feyisa, Temesgen Aferu.

Methodology: Jafer Siraj, Desalegn Feyissa, Fikadu Ejeta, Gemmechu Hasen, Tesfaye Mohammed.

Project administration: Yitagesu Mamo, Ameha Zewudie.

Resources: Ameha Zewudie, Diriba Feyisa.
Software: Desalegn Feyissa, Fikadu Ejeta, Gemmechu Hasen.
Supervision: Amela Zewude, Diriba Feyisa.
Validation: Tolcha Regesa, Gemmechu Hasen, Tesfaye Mohammed.
Visualization: Tolcha Regesa, Diriba Feyisa, Gemmechu Hasen, Tesfaye Mohammed.
Writing – original draft: Jafer Siraj, Desalegn Feyissa, Temesgen Aferu.
Writing – review & editing: Jafer Siraj, Desalegn Feyissa, Tesfaye Mohammed.

References

[1] WHO. Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector: Progress Report; 2007.
[2] UNAIDS. United Nations Political Declaration on Ending AIDS Data 2017; 2017.
[3] Brhane BG, Nibret E, Abay GK. HIV/AIDS treatment failure and its determinant factors among first line HAART patients at Felege-Hiwot Referral Hospital, Bahir Dar, Northwest Ethiopia. AIDS Clin Res 2017;8: doi: 10.4172/2153-6113.1000744.
[4] WHO. Towards Universal Access: Scaling up Priority HIV/AIDS Interventions in the Health Sector; Progress Report; 2009.
[5] UNAIDS. Global AIDS Monitoring 2018: Indicators for Monitoring the 2016 United Nations Political Declaration on Ending AIDS; 2018.
[6] Aldous JL, Haubrich RH. Defining treatment failure in resource-rich settings. Curr Opin HIV AIDS 2010;4:459–66.
[7] WHO. Antiretroviral Therapy for HIV Infection in Adults and Adolescents: Recommendations for a Public Health Approach [2010 Revision]; 2010.
[8] WHO. Towards Universal Access: Scaling Up Priority HIV/AIDS Interventions in the Health Sector; Progress Report; 2010.
[9] Melsew YA, Terefe MW, Tesemma GA, Ayele TA. Rate of immunological failure and its predictors among patients on highly active antiretroviral therapy at Debremarkos Hospital Northwest Ethiopia: a retrospective follow up study. AIDS Clin Res 2013;4: doi: 10.4172/2153-6113.1000211.
[10] Ayalew MB, Kumilachew D, Belay A, et al. First-line antiretroviral treatment failure and associated factors in HIV patients at the university of Gondar teaching hospital, Gondar, Northwest Ethiopia. HIV/AIDS Res Palliat Care 2016;8:141–6.
[11] Endalamaw A, Mekonnen M, Gererew D, Yehualashet FA, Tesera H. HIV/AIDS treatment failure and associated factors in Ethiopia: meta-analysis. Published online 2020;1–13.
[12] Assemie MA, Alene M, Ketema DB, Mulatu S. Treatment failure and associated factors among first line patients on highly active antiretroviral therapy in Ethiopia: a systematic review and meta-analysis. Glob Heal Res Policy 2019;4:1–10.
[13] Cadosch D, Bonhoeffer S, Kouyos R. Assessing the impact of adherence to anti-retroviral therapy on treatment failure and resistance evolution in HIV. J R Soc Interface 2012;9:2309–20.
[14] Datay MI, Boulle A, Sa F, Mant D, Yudkin P. Associations with virologic treatment failure in adults on antiretroviral therapy in South Africa 2010;54:489–95.
[15] Kassa D, Gebremichael G, Alemayehu Y, Wolday D, Messele T, Baarle D Van. Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, Ethiopia. Published online 2013;1–12.
[16] Lindsey JC, Hughes MD, Violari A, et al., for the P1060 Study Team. Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior Nevirapine exposure for the prevention of mother-to-child HIV transmission. Pediatr Infect Dis J 2015;33:846–54.
[17] Hassan AS, Nabwera HM, Mwaringa SM, et al. HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: a cross-sectional study. Published online 2014.
[18] Wabe N, Regional A, Bureu H, Dar B, Sciences M. Causes for antiretroviral regimen change among HIV /AIDS patients in Addis Ababa. Ethiopia 2013;15:1–9.
[19] Estill FN, Salazar-Vizcaya I, Haas A, Blaser N EM, et al. The estimated need of second-line antiretroviral therapy in sub-Saharan Africa 2015–2030; mathematical modelling study. In: 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention; 2015.
[20] Petersen , et al. Long term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification. AIDS 2008;22:2097–106.
[21] Rami Kantur , Lameck Diero , Allison DeLong , et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2016;49:454–62.
[22] El-khatib Z, Katzenstein D, Marrone G, et al. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLOS ONE 2011;6: doi: 10.1371/journal.pone.0017518.
[23] Mutevedzi PC, Lessells RJ, Rodgers AJ, Newell M. Association of age with mortality and virological and immunological response to antiretroviral therapy in Rural South African Adults. PLoS One 2011;6:e21795.
[24] Anthony Kapesa , et al. Determinants of immunological failure among clients on the first line treatment with highly active antiretroviral drugs in Dar es S alam Tanzania. Asia Pac J Tropical Med Press 2014;4(Suppl 2): S620–4.
[25] FMOH. Guidelines for Management of Opportunistic Infections and Anti-Retroviral Treatment in Adolescents and Adults in Ethiopia, March 2008; 2008. Available at: https://www.who.int/hiv/pub/guidelines/ethio-pia_art.pdf. Accessed October 21, 2018.
[26] OARAC. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection What’s New in the Pediatric Guidelines; 2020.
[27] Khuenprasit N, Chaiwarith R, Sirisanthana T, Supparatpinyo K. Incidence and risk factors of antiretroviral treatment failure in treatment-naive HIV infected patients at Chiang Mai University Hospital, Thailand. AIDS Res Ther 2011;8:421–7.
[28] Bayou B, Siyas AKA. Assessment of the magnitude and associated factors of immunological failure among adult and adolescent HIV-infected patients in St. Luke and Tuluabo Hospital, Oromia Region, Ethiopia. Pan Afr Med J 2015;21:291.
[29] Vanobberghen FM, Kilama B, Wringe A, et al. Immunological failure of first-line and switch to second-line antiretroviral therapy among HIV-infected persons in Tanzania: analysis of routinely collected national data. Trop Med Int Health 2015;20:880–92.